How Buccal and Sublingual Peptide Bioavailability Is Studied

Buccal and sublingual peptide bioavailability research examines how peptide formulations interact with the oral mucosa, saliva, mucus, epithelial barriers, local enzymes, and formulation-removal processes before systemic exposure is measured. Although both approaches use regions of the oral cavity, buccal and sublingual tissues differ in epithelial structure, permeability, surface area, vascular characteristics, and achievable formulation residence time. Their results therefore need to be evaluated separately and connected to the exact peptide, dosage form, placement site, residence period, analytical method, and study conditions.

Buccal and sublingual studies form part of the wider investigation of peptide bioavailability research. These routes avoid some gastrointestinal stages associated with swallowed dosage forms, but they introduce different barriers involving mucosal transport, salivary dilution, enzymatic exposure, residence time, and the possibility that part of the formulation will be swallowed.

This article is provided for general educational purposes and explains formulation, delivery, and research concepts associated with peptide bioavailability research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A measurable peptide concentration after buccal or sublingual administration does not establish that the complete administered quantity crossed the oral mucosa. Systemic measurements must be interpreted together with formulation retention, swallowed fractions, mucosal transport, and analytical controls.

What Is Buccal Peptide Delivery Research?

Buccal research places a peptide-containing formulation against the mucosal surface lining the cheek or another specifically defined buccal region.

Experimental dosage forms may include:

• films
• patches
• tablets
• gels
• sprays
• solutions
• nanoparticle-containing systems

The formulation may be designed to remain in contact with the mucosa for a predefined period while peptide release and transport are measured.

What Is Sublingual Peptide Delivery Research?

Sublingual research places a formulation beneath the tongue.

Researchers may examine formulations such as:

• rapidly dissolving films
• tablets
• sprays
• solutions
• gels
• other thin dosage forms

The sublingual region has different anatomical and residence-time characteristics from the buccal region.

Buccal and Sublingual Are Not Interchangeable Terms

Both routes involve oral mucosa, but they use different tissue regions.

Potential differences include:

• epithelial thickness
• keratinization
• vascular density
• surface area
• mucus characteristics
• saliva exposure
• formulation retention

A formulation evaluated on buccal tissue should not automatically be described as having established sublingual behavior.

Oral Mucosa Is a Barrier

For systemic exposure to occur through the mucosal pathway, peptide-related material must move from the formulation toward and across the relevant epithelial barrier.

This process may be limited by:

• peptide molecular size
• charge
• hydrophilicity
• epithelial structure
• mucus
• enzymatic activity
• limited residence time

A peptide released from a film is not necessarily a peptide transported across the mucosa.

Peptide Release Comes Before Permeation Measurement

A solid or semi-solid dosage form must release peptide-containing material before the peptide can interact with the mucosal surface.

Release may depend on:

• polymer hydration
• film dissolution
• tablet disintegration
• salivary fluid
• local pH
• formulation thickness
• peptide-polymer interactions

Incomplete release can limit how much peptide becomes available for later transport testing.

Saliva Changes the Formulation Environment

Saliva can hydrate, dilute, dissolve, redistribute, or remove formulation components.

Researchers may consider:

• saliva volume
• salivary flow
• pH
• electrolytes
• enzymatic components
• swallowing frequency

Results obtained in a static laboratory buffer may differ from those obtained under continuously changing salivary conditions.

Swallowing Creates an Interpretation Problem

Material released from a buccal or sublingual formulation may be swallowed before crossing the oral mucosa.

After swallowing, the peptide enters gastrointestinal conditions rather than remaining part of a purely transmucosal pathway.

Researchers may therefore need to consider:

• how much formulation remains at the site
• how much peptide is released
• how much is swallowed
• how much remains in the dosage form
• how much appears systemically

A systemic concentration alone may not reveal which pathway contributed to the measurement.

Residence Time Is a Key Variable

A formulation must remain at the intended mucosal location long enough for the experimental release and transport processes to occur.

Residence can be affected by:

• salivary flow
• tongue movement
• speaking
• swallowing
• dosage-form geometry
• adhesive properties
• hydration

A formulation that remains attached in a laboratory model may detach earlier under dynamic oral conditions.

Mucoadhesive Formulations

Mucoadhesive materials are investigated for their ability to retain a dosage form near a mucosal surface.

Researchers may measure:

• adhesion force
• detachment force
• residence duration
• polymer swelling
• hydration
• release during adhesion

Stronger measured adhesion does not independently establish greater peptide transport.

Adhesion and Release Can Interact

A polymer that strongly retains a dosage form may also interact strongly with the peptide.

This can affect:

• release rate
• peptide availability
• local concentration
• polymer swelling
• analytical extraction

A formulation must therefore be evaluated for both residence and peptide release.

Mucus Interaction

Peptide and formulation components may interact with mucus before reaching epithelial cells.

Possible observations include:

• mucin binding
• retention near the surface
• slower diffusion
• aggregation
• changes in mucus structure

Greater local retention may increase residence while reducing movement through the mucus layer.

Enzymatic Stability

Peptides may encounter enzymes in saliva, mucosal tissue, or associated biological fluids.

Laboratory studies may examine:

• disappearance of intact peptide
• fragment formation
• time-dependent degradation
• effects of formulation components
• differences among tissue preparations

Stability in one artificial saliva formulation does not establish stability in all oral environments.

Permeation Enhancers

Some formulation materials are investigated for changes they produce in peptide transport across oral mucosal models.

Experimental evaluation may include:

• peptide flux
• barrier resistance
• marker-compound movement
• tissue morphology
• cell viability
• recovery after exposure

Greater transport should be interpreted together with evidence showing how the barrier behaved during and after exposure.

Permeation Must Be Distinguished from Barrier Disruption

A large increase in peptide passage can result from several mechanisms.

Researchers may need to distinguish:

• controlled changes in membrane interaction
• paracellular changes
• transcellular movement
• loss of tissue integrity
• experimental leakage

Transport data are difficult to interpret without barrier-integrity controls.

In Vitro Buccal Models

Laboratory models may use artificial membranes, cultured cells, reconstructed tissue, or excised mucosa.

Researchers may measure:

• peptide release
• transport rate
• tissue retention
• donor concentration
• receiver concentration
• barrier integrity

Each model reproduces only selected characteristics of the human oral cavity.

Excised Tissue Models

Excised buccal or sublingual tissue may preserve anatomical barriers better than a simple artificial membrane.

Interpretation can depend on:

• species
• tissue region
• tissue thickness
• time after collection
• storage conditions
• orientation
• viability

Animal mucosa and human mucosa may differ in permeability and structure.

Diffusion Cells

Franz-type and related diffusion systems can place mucosal tissue between donor and receiver compartments.

Measurements may include:

• peptide disappearance from the donor
• appearance in the receiver
• peptide retained in tissue
• mass balance
• time-dependent flux

The apparatus does not reproduce salivary flow, swallowing, blood flow, or normal oral movement.

Peptide Flux

Flux describes the amount of peptide crossing a defined area over a defined period.

It may depend on:

• donor concentration
• surface area
• tissue thickness
• formulation composition
• temperature
• sampling period

A flux value is specific to the experimental model and should not be converted directly into a human systemic exposure prediction without additional evidence.

Apparent Permeability

Researchers may calculate an apparent permeability coefficient to normalize transport measurements for concentration and surface area.

The value may change with:

• model type
• peptide concentration
• tissue source
• formulation
• sampling method
• barrier condition

Values from unrelated laboratory systems should not be treated as directly interchangeable.

Tissue Retention

Not all peptide that leaves the formulation appears in the receiver compartment.

Some peptide-related material may remain:

• on the mucosal surface
• within mucus
• within epithelial tissue
• bound to formulation components
• adsorbed to the apparatus

Mass-balance analysis can help determine where peptide-related material remains after the experiment.

Analytical Recovery Is Important

Peptides may adsorb to laboratory plastics, filters, membranes, or tissue surfaces.

Low receiver concentrations may therefore reflect:

• limited transport
• peptide degradation
• tissue retention
• surface adsorption
• incomplete extraction

An experiment should distinguish these possibilities where practical.

Animal Studies

Animal studies may examine complete mucosal administration and systemic concentration-time measurements.

Researchers may evaluate:

• formulation residence
• systemic exposure
• local tissue observations
• swallowed material
• peptide distribution
• variability

Translation may be affected by species differences in oral anatomy, salivary flow, epithelial structure, and swallowing behavior.

Human Studies

Human buccal and sublingual studies can measure systemic peptide concentrations after a defined formulation is placed at a specified oral location.

Study protocols may specify:

• exact placement
• residence time
• whether swallowing is restricted temporarily
• food and fluid restrictions
• formulation removal time
• blood-sampling schedule

These procedural details are part of the route definition.

Placement Consistency Matters

A film placed in a different oral location may encounter a different mucosal surface, saliva flow, or movement pattern.

Studies may need standardized instructions covering:

• placement region
• orientation
• pressure during application
• contact duration
• movement during the study

Variation in placement can contribute to exposure variability.

Dosage-Form Dissolution Time

A rapidly dissolving sublingual film and a longer-residence buccal patch create different release conditions.

Dissolution or erosion time may affect:

• peptide concentration at the mucosa
• fraction swallowed
• residence duration
• peptide stability
• sampling interpretation

Dosage-form type must therefore be identified when comparing studies.

Buccal and Sublingual Exposure Should Not Be Pooled Automatically

Even if the same peptide is used, differences in tissue and formulation residence can produce different exposure measurements.

Comparisons should identify:

• the exact mucosal region
• formulation type
• placement duration
• peptide quantity
• analytical method
• swallowing controls

Absolute Bioavailability Research

A buccal or sublingual formulation may be compared with an intravenous reference under a defined pharmacokinetic protocol.

The calculation requires:

• measured systemic exposure
• known administered quantities
• appropriate normalization
• adequate sampling
• comparable peptide analysis

The resulting value describes the exact formulation and study conditions rather than the entire buccal or sublingual route.

Relative Bioavailability Research

Researchers may compare:

• two buccal formulations
• two sublingual formulations
• buccal and sublingual formulations
• mucosal and another non-intravenous route

Relative measurements require the reference formulation to be identified clearly.

Cmax, Tmax, and AUC Answer Different Questions

Human pharmacokinetic studies may report:

• Cmax for maximum measured concentration
• Tmax for timing of that maximum
• AUC for total measured exposure over time

A higher Cmax, shorter Tmax, or larger AUC should not be treated as interchangeable findings.

Variability Can Be Substantial

Buccal and sublingual exposure can vary because of differences in:

• salivary flow
• placement
• mucosal structure
• formulation retention
• swallowing
• individual epithelial permeability

Individual concentration-time profiles can therefore be important alongside group averages.

Transmucosal Research Has Route-Specific Barriers

A 2024 review indexed by the National Library of Medicine examines protein and peptide transport across nasal, buccal, sublingual, and oral mucosal barriers, including the physicochemical characteristics that can limit macromolecular movement.

Such research supports treating each mucosal region as a defined experimental environment rather than assuming all mucosal delivery behaves similarly.

Mucosal Routes Should Not Be Ranked Against Oral or Injectable Routes Alone

A buccal or sublingual result should be compared only when the peptide, formulation, reference condition, administered quantity, sampling, and analysis are sufficiently comparable.

The broader route-comparison problem is explained in Oral vs Injectable Peptide Bioavailability: What Can Be Compared?.

What Buccal and Sublingual Studies Can Establish

A well-designed study may establish that under defined conditions:

• a formulation releases measurable peptide
• peptide crosses a selected mucosal model
• the formulation remains at the site for a measured period
• systemic peptide-related exposure is measurable
• two formulations produce different exposure profiles
• transport changes with formulation composition

What These Studies Do Not Establish

Buccal or sublingual research does not automatically establish:

• that all peptide formulations cross oral mucosa
• that buccal and sublingual results are interchangeable
• that all measured systemic peptide crossed the mucosa
• results in another population
• equivalence to another route
• a universal route ranking
• performance of another peptide

Final Perspective

Buccal and sublingual peptide bioavailability research examines a sequence involving dosage-form release, saliva, residence time, mucus, epithelial transport, swallowed fractions, tissue retention, and systemic measurement.

Although both routes use oral mucosa, their tissue structure, placement, fluid exposure, and residence characteristics differ enough that they should be evaluated separately.

Accurate interpretation identifies the exact peptide, formulation, mucosal region, residence period, release measurement, barrier model, swallowed fraction, systemic exposure, analytical method, and variability rather than treating buccal or sublingual administration as a general predictor of peptide bioavailability.